Improving the prediction of medication compliance: the example of bisphosphonates for osteoporosis - Wikidata - wikimedia - TriplyDB

Improving the prediction of medication compliance: the example of bisphosphonates for osteoporosis

Improving the prediction of medication compliance: the example of bisphosphonates for osteoporosis

http://www.wikidata.org/entity/Q37221438

about

Predicting persistence to antidepressant treatment in administrative claims data: Considering the influence of refill delays and prior persistence on other medications.Patterns and predictors of osteoporosis medication discontinuation and switching among Medicare beneficiaries Understanding prescription adherence: pharmacy claims data from the Contraceptive CHOICE Project Adherence with statins in a real-life setting is better when associated cardiovascular risk factors increase: a cohort study Adherence to osteoporosis treatments: room for improvement Low acceptance of treatment in the elderly for the secondary prevention of osteoporotic fracture in the acute rehabilitation setting Does medication adherence itself confer fracture protection? An investigation of the healthy adherer effect in observational data Oral bisphosphonate compliance and persistence: a matter of choice?Healthy user and related biases in observational studies of preventive interventions: a primer for physicians.Personality and medication non-adherence among older adults enrolled in a six-year trial.Measuring and improving adherence to osteoporosis pharmacotherapy.Obedience and motivation as mechanisms for adherence to medication: a study in obese type 2 diabetic patients.Assessing adherence to teriparatide therapy, causes of nonadherence and effect of adherence on bone mineral density measurements in osteoporotic patients at high risk for fracture.Medication Nonadherence Is Associated With Increased Subsequent Acute Care Utilization Among Medicaid Beneficiaries With Systemic Lupus Erythematosus.Observing versus Predicting: Initial Patterns of Filling Predict Long-Term Adherence More Accurately Than High-Dimensional Modeling Techniques.Why is greater medication adherence associated with better outcomes.Simplistic and complex thought in medicine: the rationale for a person-centered care model as a medical revolution.Bisphosphonates adherence for treatment of osteoporosis.Association between gastrointestinal events and compliance with osteoporosis therapy.Osteoporosis medication adherence: physician perceptions vs. patients' utilization.Cost-related nonadherence by medication type among Medicare Part D beneficiaries with diabetes.Improving treatment adherence in patients with rheumatologic disease.Predictors of fracture while on treatment with oral bisphosphonates: a population-based cohort study.Adherence to therapies in patients with type 2 diabetes.Overcoming problems with adherence to osteoporosis medication.Medical specialty-related adherence to anti-osteoporotic regimens in fragility hip fracture patients.How to study determinants related to medication adherence in newly diagnosed polyarthritis patients for the development of a prediction instrument Fractures and mortality in relation to different osteoporosis treatments.The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis.Commentary: measuring quality of care in osteoporosis.Assessment of geriatric predictors of adherence to Zoledronic acid treatment for osteoporosis: a prospective follow-up study.Advancing the Science and Practice of Medication Adherence.Understanding patient compliance and persistence with osteoporosis therapy.Healthy users, healthy adherers, and healthy behaviors?Adherence and persistence of patients using oral bone sparing drugs in primary care.

P2860

Q31049668-BC998D59-98A2-49A2-8DCC-12896854BD7F Q33617272-025EBC9F-A7E2-4C4E-8720-39B49CDE039C Q33844202-CF219A55-E6C3-431A-BE81-6164CF3D9EE1 Q33972105-E2A82D05-347C-4108-810A-844F7F29F9FF Q34033742-C1411A84-9FFA-4681-AF99-6CF878E81F4F Q34055595-4FBFC97B-7B4B-46F5-9957-3EC26C2B607B Q34316224-533202DD-519A-414C-AEA7-F68AFEE2F537 Q34472700-882D6E5E-3FC4-4B0C-89DB-84F2E3881729 Q34799001-E430B277-9DC5-4585-89D3-F2BA3539C317 Q35077839-43A71039-FCBC-4641-B046-CB5A864E40A7 Q35177690-CDA36D73-B26E-427F-A418-677265B1BB99 Q35555613-25C37998-16D3-4C23-96BC-1C12097D15FD Q36056911-C58DE0DC-1DCF-4D05-AC84-B40195A7B62E Q36386474-3E35DC55-8712-49F3-97DF-9A44A1A09B14 Q36488716-D5A8EDBF-1741-4887-9C2F-950193C095D9 Q36707347-C323C688-7E4A-40BC-9EE0-3B123D6B0492 Q36791336-D0E3A040-A11F-4B49-9E12-CA6A5672C315 Q36908527-A67A5E4D-0629-4B7B-891C-82EC15B36FD0 Q37051660-6BD23338-0A84-4CEA-B888-17064C514093 Q37183237-34DC21BE-8DB8-480F-9ABA-B0DE83D31153 Q37191246-AE646643-63AF-4CD2-AB18-C557910C01BC Q37196980-1DEA6F9A-0178-4316-8CB5-56BCB658BD3E Q37401919-3FF858F2-B211-4277-BF82-0D1FA2A65C62 Q37468440-F38C4A9F-B4E3-4C7E-AC43-B5FC711D7EF3 Q37820680-AEAA6E7E-07AA-4111-B964-29196EA473F7 Q38252857-3E4392C6-8345-41D6-B2DD-D6138BD29899 Q38263170-265D5CCE-2376-48E6-A9A6-50A1A483F045 Q43577539-2D864BDB-2333-4CFD-83E0-E5D0042A5388 Q44892769-95C7CCCC-249F-4A67-B051-3522500A28B8 Q45914941-AB1D2DC8-7CA6-4CB7-BB94-2ACDF7F86081 Q47563434-20F6179E-0F16-4179-8FF6-1DF31CE5B3E5 Q47567525-958B2B33-0E10-425C-8EC0-CE00892A3ED2 Q50629816-B8BC33FF-0DD1-4ACD-985F-5BA03D04D26E Q53082495-86EACD75-89D8-4B3E-8393-09FB31C6AD32 Q53407067-EC30EB29-173E-4BDD-9CED-AABF24B9C7DC

P2860

Improving the prediction of medication compliance: the example of bisphosphonates for osteoporosis

http://www.wikidata.org/entity/Q37221438

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Improving the prediction of me ...... sphosphonates for osteoporosis

@en

Improving the prediction of me ...... phosphonates for osteoporosis.

@nl

type

label

Improving the prediction of me ...... sphosphonates for osteoporosis

@en

Improving the prediction of me ...... phosphonates for osteoporosis.

@nl

prefLabel

Improving the prediction of me ...... sphosphonates for osteoporosis

@en

Improving the prediction of me ...... phosphonates for osteoporosis.

@nl

P1433

Q37221438-3DE74E79-2C15-4EC4-8BDD-78214F1B516A

P1476

Q37221438-7A4BEA03-A12D-4BF1-8969-B47879CE4E8A

P2093

Q37221438-3B396A83-5592-40A9-B2D0-3215AF8285A5

Q37221438-43285428-EE59-45CC-9331-95677C66625C

Q37221438-5EF0D985-BD1A-46CB-B6E3-8170DAFF8E22

Q37221438-65F7E31C-41EA-4F47-B7FB-D3B8828F031C

Q37221438-6E8DADBE-814E-41E3-919C-7360D799C0CE

Q37221438-A4E346C6-7B07-4A60-ADE5-7FBAE96828B5

P2860

Q37221438-12649383-E871-444B-8F5A-7CE803F15982

Q37221438-18AC5CB3-C45A-4304-81BE-4C393421509C

Q37221438-18F5927E-CF59-4C60-B176-10F92ED421F5

Q37221438-3CF961E9-EE7C-4D6E-A482-89B20BCB93FD

Q37221438-4798170C-6208-4AE0-B53D-2372E9E9BD39

Q37221438-55A92D86-AEBD-407F-A62C-CBCDC980A399

Q37221438-74FD4A98-03AD-49E6-AF7E-605788C2526B

Q37221438-75DFD074-C5D3-4A5C-A72E-11CEDF1F2302

Q37221438-7723A50E-2DAA-492A-90F7-6116BA3E1314

Q37221438-77866361-1BA1-469D-90A9-427A7B34891D

P304

Q37221438-BC7FA9E3-E4E1-4230-8C53-66E68571929F

P31

Q37221438-CAE82861-2F0C-48CB-BF8B-05224C3975F1

P356

Q37221438-B4E31907-8280-47A2-936F-47261296F53E

P433

Q37221438-9F080BD3-4F90-439C-A2DB-10A94F51F947

P478

Q37221438-5FE82B53-7EAE-473B-AC6E-CD62E07B54B2

P50

Q37221438-956A259A-890A-46A5-A497-E4D3A6CA1A74

P577

Q37221438-B841FD30-F2D6-4207-908C-F3E86C0287A7

P698

Q37221438-C0C4F8D8-5372-4833-A35D-6256EED3FDD1

P921

Q37221438-9FD6BD72-4BFA-4390-9E13-028DCA344682

P932

Q37221438-E71A8E53-13AF-41C3-B81B-D97FBB412814

P356

MLR.0B013E31818AFA1C

P1433

P1476

Improving the prediction of me ...... sphosphonates for osteoporosis

@en

P2093

Elizabeth Delzell

http://www.w3.org/2001/XMLSchema#string

Hong Cheng

http://www.w3.org/2001/XMLSchema#string

Jeffrey R Curtis

http://www.w3.org/2001/XMLSchema#string

Juan Xi

http://www.w3.org/2001/XMLSchema#string

Kenneth G Saag

http://www.w3.org/2001/XMLSchema#string

Kenneth Lyles

http://www.w3.org/2001/XMLSchema#string

P2860

Estimating medication persistency using administrative claims data.

Persistence with treatment for hypertension in actual practice.

Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.

Review of adherence to medications for the treatment of osteoporosis.

Loss of treatment benefit due to low compliance with bisphosphonate therapy.

Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases.

Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users.

Comparison of drug adherence rates among patients with seven different medical conditions.

Concurrent and predictive validity of a self-reported measure of medication adherence

A review of goodness of fit statistics for use in the development of logistic regression models.

P304

334-341

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/MLR.0B013E31818AFA1C

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

47

http://www.w3.org/2001/XMLSchema#string

P50

Andrew O Westfall

P577

2009-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19194337

http://www.w3.org/2001/XMLSchema#string

P921

P932

2693955

http://www.w3.org/2001/XMLSchema#string